Royalty Report: Drugs, Cannabis, Cancer – Collection: 372460

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Cannabis
  • Cancer
  • Therapeutic
  • Medical
  • Delivery
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372460

License Grant
Licensor of Japan grants to Licensee of the United Kingdom under the Collaboration IP, the nonexclusive right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research, make, have made and use  Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan.

This agreement is for the research and early stage development of pharmaceutical preparations based upon Research Compounds (as defined below) for the treatment of CNS and cancer indications.

License Property
Licensor has intellectual property of botanical extracts from chemovars of Cannabis sativa for the treatment of CNS and cancer indications.

Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.

Botanical Drug Candidate or BDC shall mean
—  any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
—  a combination of two or more Phytocannabinoid extracts described above containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and,
—  any biological or chemical modification of the Phytocannabinoids in above including any metabolite or degradant.

Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid) or outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).

Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).

Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabiooid but which has been developed with information resulting from the Research Collaboration and for which one or more patent.

Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.

Field of Use
The  fields of use are neuropsychopharmacology, with special reference to schizophrenia; cannabinoid/opioid analgesic combinations; and, oncology.

The Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.

IPSCIO Record ID: 384961

License Grant
By this agreement, for the Clinical Development of product candidates, Licensee may chose Product Candidates, if any, for Clinical Development. Licensee of Japan shall notify Licensor of the United Kingdom in writing of whether it is has chosen one or more Product Candidates.

Upon notice by Licensee to Licensor from time to time during the period permitted therefor pursuant to this Agreement, Licensor shall granted to Licensee under Collaboration IP and Licensor Background IP, without the need for further action by either of the Parties, an exclusive, license to make, have made, use, offer for sale, sell, import and otherwise exploit the Product Candidates referenced in such notices in the Territory in the Research Field.

Licensor of the United Kingdom grants to the Licensee of Japan under Licensor Background IP and Collaboration IP, the sole right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research and use Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan but excluding the right to manufacture Research Compounds or have Research Compounds manufactured on its
behalf other than by Licensor. This right shall not be capable of sub-license.

License Property
Licensor has expertise in the research and development of pharmaceutical preparations based upon botanical extracts from chemovars of Cannabis sativa, and, has proprietary knowledge and interests in the research and development of pharmaceutical preparations based upon botanical extracts from different chemovars of Cannabis sativa in addition to that combination of botanical extracts used in SATIVEXâ„¢ oromucosal spray.

Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.

Botanical Drug Candidate or BDC shall mean
—  any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
—  a combination of two or more Phytocannabinoid extracts described containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and
— any biological or chemical modification of the Phytocannabinoids including any metabolite or degradant.

Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid), or, outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).

Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).

Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabinoid but;
—  which has been developed with information resulting from the Research Collaboration and,
—  for which one or more patent· applications have been filed by Licensee on an invention conceived within three years following expiration of the Research Term or any Extended Research Term claiming a novel composition of matter and a cannabinomimetic or cannabinergic effect through direct, or indirect (i.e. modulation of related metabolic enzyme systems), effects on one or more cannabinoid receptors (including their allosteric sites).

Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.

Field of Use
The field of use is neuropsychopharmacology, with special reference to schizophrenia, cannabinoid/opioid analgesic combinations, and, oncology.

Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.

IPSCIO Record ID: 359060

License Grant
The Parties entered into a sponsored research agreement to conduct research and development efforts relating to Licensors COVID-19 and rheumatoid arthritis (RA) product candidates. The focused is on characterizing the activity of cannabinoids in RA and in hyperinflammatory syndrome related to COVID-19.

In accordance with the terms of the Research Agreement, Israelis Licensee and Israelis Licensor will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Licensor agreed not to work, study or develop any technologies with other entities that compete with our work with Licensor for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.

License Property
Cannabidiol, or CBD, oil is derived from CBD strains with low levels of Tetrahydrocannabinol, or THC. The discovery platform currently focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient, or API, for our RA product candidate and COVID-19 product candidate.

The Licensor  have been conducting research on the use of cannabis to treat disorders with widespread inflammatory responses, such as RA and COVID-19. Parties hope that by decoding the cannabinoid mechanism of action during inflammatory storms, the Parties can treat inflammation associated with COVID-19 where conventional drugs and other therapies have failed.

Field of Use
Field of use is for the treatment in RA and in hyperinflammatory syndrome related to COVID-19.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder. COVID-19 is a virus infection.

IPSCIO Record ID: 301640

License Grant
Sublicensor hereby grants to Sublicensee, and Sublicensee hereby accepts, a transferable, non-exclusive right and license under the Licensed Science to make or have made the Licensed Products and to use the Licenses Science Patents, Know-How, and Licensed Products in connection with the Field, including the distribution, sale, and marketing thereof, in the Territory.

The Licensed Science Sublicense granted is for the purpose of engaging in the business of treating, producing, manufacturing, marketing and selling Licensed Products.

License Property
Licensed Products means any CBD products related to the Field, whether owned by Licensor or Sublicensor or licensed by Licensor or Sublicensor now or hereafter, that are covered by any Valid Claim(s) contained in any of the Patents, and/or based on the products, processes or methods developed using the Licensed Science.

The Licensed Science as its relates to the production, methods, and products of CBD and its derivatives.

Field of Use
Field means the
(a) production and manufacturing of CBD, CBD byproducts and CBD derivatives, from non-psychoactive, low-THC cannabis sativa plant strains and cannabinoids (collectively, Cannabis), for Sale and use at retail or wholesale where permitted, including, without limitation, CBD food additives, CBD edibles, and CBD hemp variations of the foregoing;
(b) CBD-related research, teaching and education for both medical and other purposes; and
(c) all medical uses and applications of CDB.

The Field is exclusive to production, methods, and products of CBD and its derivatives, and excludes and prohibits any THC related products having measurable tetrahydrocannabinol concentration potency above 3.0% on a dry weight basis, production methods, techniques, or Know How.

IPSCIO Record ID: 318266

License Grant
Licensee has the exclusive right from the University for the commercial development and exploitation of the study results, with respect to the research results relating to the synthesis of novel cannabinoid dual-action compounds and novel chemical derivatives of cannabigerol and tetrahydrocannabivarin.
License Property
Cannabinoid (CB1)  and novel chemical derivatives are receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.

University is a pioneer in the research of the endocannabinoid system and the research to synthesize novel cannabinoids cannabinoid-based dual-action compounds and novel chemical derivatives based upon the molecular structure of existing cannabinoids. Both of these programs are intended to provide series of proprietary NCEs for evaluation as potential drug candidates.

Field of Use
The field of use is for the treatment of various cancers and systemic sclerosis, or SSc. Over-activation of CB1 and iNOS has been implicated in the pathophysiology of SSc, which includes fibrosis of the skin, lung, kidney, heart and the gastrointestinal tract.  These synthetically-derived cannabinoids, or derivatives thereof, are found in cannabis for medical purposes.

Licensee is a biopharmaceutical company developing transformational therapeutics targeting immuno-oncology gene therapy for the treatment of multiple cancers through the research and development of the drug candidates,.

IPSCIO Record ID: 249597

License Grant
In this related party agreement, the Company executed five exclusive pharmaceutical license agreements with the Company’s CEO, the Company’s CMO, three advisory board members of the Company, and an unrelated third party. These agreements provide the Company the worldwide exclusive rights to certain drug technologies and methods (and systems) for collection, processing and use of data for the dispensing of phyto-medical and botanically derived materials for consumption. The license agreements grant to the Company from the inventors the rights to develop, market, make, use, and sell certain drug formulations, which are applied to humans through the use of certain drug technology.
License Property
The Licensor parties are part of a developmental stage phyto-medical/pharmaceutical and drug discovery company that specializes in the research, development of cannabinoid and cannabinoid-based therapeutic products derived from synthetic and botanical sources, including the Cannabis “taxa” (the word “taxa” is the plural of “taxon” which defines a group of one or more populations of an organism or organisms to form a unit.)

Cannabinoids are a class of compounds derived from Cannabis plants. The two primary cannabinoids contained in Cannabis are cannabidiol, or CBD, and D9-tetrahydrocannabinol, or THC. Clinical and preclinical data suggest that CBD has positive effects on treating refractory epilepsy, FXS and arthritis and THC has positive effects on treating pain.

Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 204556

License Grant
Licensor grants to Licensee exclusive Worldwide rights to BiPhasix Transdermal Drug Delivery Technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products.
License Property
The term “Product” shall mean any pharmaceutical product, development candidate for human or animal use arising out of the collaboration based on the BiPhasix CBD Intellectual Property Rights.

Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.

BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.

Field of Use
The rights are to BiPhasixâ„¢ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.

The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.

IPSCIO Record ID: 266631

License Grant
Licensor hereby grants to Licensee an exclusive, world-wide, License to use the HDI Technology solely in the Cannabis Application, for the purpose of processing Cannabis Materials using the SPR in the Cannabis Industry. (The aforesaid license grant is herein sometimes referred to as the “License”).

Licensor grants an exclusive license to all Licensors Intellectual Property and patented technology and creates a partnership to bring their patented controlled cavitation process to the cannabis industry.

License Property
Licensor has the Shockwave Powerâ„¢ Reactor (SPR) rights for mixing and Heating, Hydrogenating Substances, Continuous Hydrodynamics cavitation crystallization, and four other patents.

Licensor is the owner of certain Technology called ShockWave Power™. Licensor owns Intellectual Property (“IP”, defined below), manifested in Patents, Trade Secrets, and Know How, which are embodied in Licensor's proprietary ShockWave Power Reactor/Extractor (“SPR™), and which IP is useful in a variety of industries including but not limited to those industries that extract, mix, heat, hydrate, homogenize and crystallize materials.

“Cannabis Industry” means the industry where cannabis oils and other compounds containing cannabis (“Cannabis Materials”, defined below) are derived from the cannabis sativa, cannabis indica, and cannabis ruderalis plants, including marijuana and hemp, either singularly or by mixing with substances other than cannabis oils.

“Cannabis Application” means the use of the Licensor Technology to achieve a specific result when processing only “Cannabis Materials”.

“ShockWave Power Reactor/Xtractor (SPR™”) means HDI’s proprietary device that embodies the HDI Technology in performing multiple heating, mixing and extraction functions.

“ShockWave Power Reactor/Xtractor (SPR™”) means HDI’s proprietary device that embodies the HDI Technology in performing multiple heating, mixing and extraction functions.

“Standalone SPR” means an SPR mounted on a skid containing no other equipment other than that necessary to run the SPR.

Field of Use
Illustrative, but not all, areas of use of the Licensed Technology covered by this Agreement are
(i) UV light for decarboxylation of THC
(ii) Crystallization of CBD or THC
(iii) mixing of cannabis oil with other substances to create foods, beverages, or other products which are themselves not cannabis oils
(iv) Use of Electrochemistry or UltraViolate (UV) SPR’s or other advanced oxidation materials to produce radicals for the production of CBN
(v) Hydrogenation of cannabis oils
(vi) processing of hemp oils for biofuels.
(vii) Development of an SPR for supercritical CO2

IPSCIO Record ID: 352096

License Grant
Inventor has assigned the entire right, title, and interest in the Assigned Patent Applications, inventions and improvements therein, and Letters Patent (referred to herein collectively as the Innovation) to Assignee and to the extent Assignee grants a license of the Innovation, or any part thereof, to any third party, and receives Revenue therefrom, then Assignee agrees to pay to Assignor a percentage of Revenue received in the aggregate by Assignee from all such licensees granting rights to the Innovation, distributed by Assignee.
License Property
Assigned Patent Applications shall mean the Patent Applications listed.
Provisional Application No. 62/632,448
United States Application No. 16/612,472
Field of Use
Field of use is for the treatment of various diseases in the Medical industry.

IPSCIO Record ID: 351634

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive (even as to Licensor and its Affiliates), irrevocable, perpetual, sublicensable, royalty-bearing license to the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale, market, export, import and otherwise commercialize and exploit the Agents and Products in the Territory.
License Property
Licensor has created a highly advanced chemistry drug discovery platform that combines cannabinoids with other molecules to create new drug candidates with potentially greater efficacy and a more favorable side effect profile than standard therapy.

Product shall mean any pharmaceutical composition or formulation including, constituting, or incorporating, any Agent.

Agent means Cannabinoid

Licensor Patent Rights shall mean all Patent Rights Covering any Agent or Product, or the use or manufacture thereof, and such Patent Rights are set forth, as amended from time-to-time. For clarity, Licensor Patent Rights excludes Patent Rights set forth that do not Cover any Agent or Product, or the use, manufacture, or sale thereof.
PCT/US2020/039234 (WO/2020/263888)         JUNE 24, 2020       CANNABINOID CONJUGATE MOLECULES
PCT/US2020/039267                          

JUNE 24, 2020
CONJUGATE MOLECULES

Field of Use
Field shall mean supportive care for conditions associated with cancer treatment or palliative care as described by the National Cancer Institute (NCI) Dictionary of Cancer Terms (e.g., care given to improve the quality of life of patients who have a serious or life-threatening disease), the goal of which is to prevent, treat, or manage as early as possible the symptoms of a disease or condition, side effects caused by such prevention, treatment, or management thereof, and psychological, social, and spiritual problems related thereto.

IPSCIO Record ID: 235008

License Grant
Licensor hereby grants Licensee, including Licensees Affiliates,

(a) during the Term, a royalty-bearing, Territory-wide license in the Licensed Field under the Patent Rights to the Licensed Technology, as well as under the Licensed Patents, the Licensed Know-how, and the Licensed Technology, regardless of whether such Licensed Patents are actually granted, to use the Licensed Know-how and Licensed Technology and to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported, any and all inventions claimed in the Licensed Patents related to the Licensed Products and/or any compounds, chemicals, substrates, devices, tools, dies, molds or any other materials whatsoever that are useful in the development and/or manufacturing and/or sale of the Licensed Products, and particularly including, without limitation, such license to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported Licensed Products, which license shall be exclusive even as to Licensor, and

(b) the right to grant bona fide sublicenses to third parties, to develop and have developed, to make and have made, use and have used, sell and have sold, import and have imported, export and have exported, Licensed Products, and to exercise all other rights under the License; provided, however, Licensee shall not have the right to grant any sublicense or to transfer any of its rights under the License unless each such sublicense or other transfer granted by Licensee contains terms and conditions under which the Sublicensee or transferee will be bound in the same manner as Licensee is under this Agreement. A copy of the proposed agreement shall be provided to Licensor prior to the execution of the Agreement.

License Property
Lcensed Products shall mean any and all products comprising tablets with Cannabinoids) utilizing the Licensed Technology for the delivery of a recreational, Medicinal or Pharmaceutical Cannabinoids product in specific dosage forms.

Cannabinoids means any of the chemical compounds that are the active components of the Cannabis genus of plants and its three species, Cannabis sativa, Cannabis indica, and Cannabis ruderalis; whether the compounds are synthetically produced or plant-derived, as well as cannabinoid compounds, formulations or products, that include single and/or multiple Cannabinoids including both synthetic and plant-derived Cannabinoids, as well as any and all Cannabinoid analogues. For formulations or compounds which may include combinations of API’s, other than Cannabinoids or terpenes, it is being agreed that if the API is another FDA approved Pharmaceutical, Licensor approval will be required to ensure that the API is not the subject of a current Licensor product, or the product of another licensee of the Licensor.

Medicinal shall mean any product containing marijuana, hemp or cannabis produced and sold for health, wellness, or nutritional purposes, including as herbal medicine, including products produced or sold through U.S. state-licensed or regulated marijuana programs and comparable programs in other countries and jurisdictions.

Licensed Technology shall mean the aggregate of the Licensed Inventions, the Licensed Know-how, the Licensed Products and the Licensed Patents and any other information and/or technology related to the Licensed Products and/or the design and/or the manufacturing of the Licensed Products

Licensed Patents shall mean any and all rights arising out of or resulting from (i) the patents and patent application set forth in Schedule 1.14 attached to this Agreement, as well as any additional patents or patent applications related to any aspect of any Licensed Technology Improvements, Licensed Know-how, Licensed Products, and/or Licensed Technology (as herein defined) filed prior to or during the term of this Agreement and (ii) any patent granted in respect of all such applications, as well as, without limitation, any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, re-examinations, extensions, supplementary protection certificates, confirmations, registrations, revalidations and the like, of any and all such patents and patent applications and any international equivalents thereof.

Field of Use
Licensed Field shall mean the use of Cannabinoids, together with the Licensed Technology for recreational, Medicinal and Pharmaceutical purposes in humans and animals.

IPSCIO Record ID: 293157

License Grant
The Israeli Licensor, the technology transfer company of the University, granted Licensee a worldwide exclusive license to develop and commercialize certain patents, know-how and research results (collectively, the 2018 Hebrew Licensed Technology), in order to develop, manufacture, market, distribute or sell products, all within the use of the 2018 Hebrew Licensed Technology.
License Property
Licensor will undertake research and to synthesize chemical compounds that will be used by Licensee, through additional research at two Universities, to develop orally active analgesic and anti-inflammatory medications. Compounds will be shipped from University to Oxford for use in pre-clinical studies to establish efficacy in pain and inflammation.
Field of Use
This agreement pertains to the drug industry for the treatment of any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the 2018 Field).

The license is to develop and commercialize certain patents in order to develop, manufacture, market, distribute, sell, repair and refurbish products, all within the use of the 2019 Hebrew Licensed Technology for (i) Cannabinoid phenolate metal salts, including mono, di and trivalent metals such as Li, Na, K, Ca, Mg, Zn, Fe and Al and their mixtures with native or synthetic cannabinoids, their pharmaceutical formulations, including for oral and topical administration; and (ii) pharmaceutical formulations, for the administration of cannabinoid chemical derivatives, including any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the “2019 Field”).

IPSCIO Record ID: 239294

License Grant
In this agreement the Licensee is to produce cannabis-infused baked goods and other edibles in Licensor’s production facility upon approval of Licensor’s Nevada Medical Marijuana Production License.
License Property
The Company (Licensor) seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
Field of Use
This agreement pertains to the drug industry relating to cannabis-based therapeutic products.

IPSCIO Record ID: 257250

License Grant
The Israeli Licensor and the Cayman Islands Licensee hereby agree to the amendment of the License Agreement (the 'First Amendment') to amend the product definition and the royalty consideration for Over the Counter Pharmaceutical Products.
License Property
Pharmaceutical Product shall mean, with respect to each jurisdiction in which it is sold or intended for sale (the 'Applicable Jurisdiction'), any cannabis-based product, compound or medicine which under the laws of the Applicable Jurisdiction would be regulated and subject to approval and restrictions in the same manner and degree and for specific indications as an approved or registered pharmaceutical product (“Pharmaceutical-Level Regulation”), whether or not prescribed or used for that specific indication, and whether used or sold pursuant to a prescription or over the counter; provided, however, that for purposes of this Agreement (a) the following shall not be considered a “Pharmaceutical Product” (i) cannabis plants (including flowers) in their natural form; (ii) food supplements containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; (iii) cosmetic products containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; and (iv) cannabis-based toothpastes, (b) cannabis-based extracts, oils and mixtures shall not be considered a “Pharmaceutical Product”, unless and to the extent such extracts, oils or mixtures are or were subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation or have potency levels equal to or higher than an identical or substantially similar product which is subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation, and (c) notwithstanding the foregoing, in the event that identical or substantially similar cannabis-based products can be sold in any Applicable Jurisdiction as both a pharmaceutical product which is subject to Pharmaceutical-Level Regulation and as a medical or adult use cannabis product which is not subject to Pharmaceutical-Level Regulation, for purposes of this Agreement, the form of such cannabis-based product which is permitted to be sold without being subject to Pharmaceutical-Level Regulation shall not be considered a “Pharmaceutical Product”. '
Field of Use
Licensee is an early stage biopharmaceutical company engaged in the business of discovering, developing and commercializing drugs containing cannabinoids, which are based on a proprietary cannabinoid-based product platform, for the treatment of various diseases, disorders and medical conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.